Page 139 - 2021_07-Haematologica-web

FVIII activity and bleeding risk in hemophilia A
References
1. Biggs R, MacFarlane RG. Haemophilia and related conditions: a survey of 187 cases. Br J Haematol. 1958;4(1):1-27.
2.White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcom- mittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001; 85(3):560.
3. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand. 1976;65(2):129-135.
4.Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treat- ment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535-544.
5. Srivastava A, Brewer AK, Mauser- Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1-47.
6. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to pre- dicted factor VIII levels in patients receiving prophylactic treatment for severe hemo- philia A. J Thromb Haemost. 2009; 7(3):413-420.
7. den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011; 17(6):849-853.
8.den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the associ-
ation of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011; 17(1):41-44.
9.Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardianTM 1) using prophylactic treatment with turoctocog alfa in adoles- cent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013;19(5):691-697.
10. Kulkarni R, Karim FA, Glamocanin S, et al. Results from a large multinational clinical trial (guardianTM 3) using prophylactic treat- ment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013;19(5):698-705.
11. Lentz SR, Janic D, Kavakli K, et al. Long- term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: final results from the guardian 2 extension trial. Haemophilia. 2018;24(6):e391-e394.
12. Jimenez-Yuste V, Lejniece S, Klamroth R, et al. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoc- tocog alfa (NovoEight®), in patients with hemophilia A. J Thromb Haemost. 2015; 13(3):370-379.
13. Ozelo M, Misgav M, Abdul KF, et al. Long- term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardianTM 2 extension trial. Haemophilia. 2015;21(5):e436-e439.
14.Lee M, Morfini M, Schulman S, and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Scientific and Standardization
Committee Communication. The design and analysis of pharmacokinetic studies of coag- ulation factors. https://www.isth.org/. Last update: 21 March 2001. Accessed in September, 2017.
15. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders-- review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia. 2004;10(5):593-628.
16.Valentino LA, Pipe SW, Collins PW, et al. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia. 2016;22(4):514-520.
17.Bjorkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombi- nant factor VIII: the relationships of phar- macokinetics to age and body weight. Blood. 2012;119(2):612-618.
18. Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to han- dling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35(4):401-421.
19. Garmann D, McLeay S, Shah A, Vis P, Maas Enriquez M, Ploeger BA. Population phar- macokinetic characterization of BAY 81- 8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit. Haemophilia. 2017; 23(4):528-537.
20.Fischer K, Chowdary P, Collins P, et al. Modelling FVIII levels for predictions of zero spontaneous-joint bleeding in a cohort of severe hemophilia A subjects with target joints initiated on tertiary prophylaxis. Blood. 2016;128(22):2576.
haematologica | 2021; 106(7)
1909